Skip to content
10-K

Annual Report

Petros Pharmaceuticals, Inc. PTPI

0001410578-25-000579

← back to feed
Filed
Mar 31, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 27, 2025 53.52M sh
Capex FY 2024 · Dec 31, 2024 $24.59K
Rd Expense FY 2024 · Dec 31, 2024 $2.62M
Rd Expense FY 2024 · Dec 31, 2023 $2.41M
Gross Profit FY 2024 · Dec 31, 2024 $3.9M
Gross Profit FY 2024 · Dec 31, 2023 $4.19M
Cost Of Revenue FY 2024 · Dec 31, 2024 $1.21M
Cost Of Revenue FY 2024 · Dec 31, 2023 $1.63M
Revenue FY 2024 · Dec 31, 2024 $5.11M
Revenue FY 2024 · Dec 31, 2023 $5.82M
Shares Diluted FY 2024 · Dec 31, 2023 2.18M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$7.63M
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $13.34M
Current Liabilities FY 2024 · Dec 31, 2023 $10.77M
Total Liabilities FY 2024 · Dec 31, 2023 $21.32M
Current Assets FY 2024 · Dec 31, 2023 $20.39M
Total Assets FY 2024 · Dec 31, 2023 $33.8M
Eps Diluted FY 2024 · Dec 31, 2023 −$6.35
Eps Basic FY 2024 · Dec 31, 2023 −$6.35
Sga Expense FY 2024 · Dec 31, 2023 $9.26M
Net Income FY 2024 · Dec 31, 2023 −$8.16M
Operating Income FY 2024 · Dec 31, 2023 −$13.62M
Stockholders Equity FY 2024 · Dec 31, 2022 $16.7M